EMA CHMP gives positive recommendation to elranatamab for the treatment of relapsed or refractory myelomaAccess, MPE, MyelomaOctober 13, 2023
ESMO 2023 | Patient Advocacy Track highlights challenges in access, caregiver support and digitalisationConferences, MPEOctober 27, 2023
Sign up for the MPE webinar on ASH 2023 myeloma and AL amyloidosis highlightsAL amyloidosis, Conferences, MPE, MyelomaDecember 9, 2023
AMEN provides medical information for Arabic speakers in Israel and beyondAccess, MPEFebruary 13, 2024
MPE gives feedback on the proposed implementing act supporting the EU Health Technology Assessment regulationAccess, MPEApril 8, 2024
US FDA approves bi-weekly teclistamab dosing in relapsed/refractory myelomaAccess, MPE, MyelomaFebruary 22, 2024
Sign up for the MPE webinar “AL amyloidosis treatment updates and patient experiences on new therapies”AL amyloidosis, MPEMarch 27, 2024
